Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 33 studies | 39% ± 20% | |
fibroblast | 23 studies | 28% ± 13% | |
classical monocyte | 16 studies | 27% ± 9% | |
microglial cell | 16 studies | 60% ± 19% | |
dendritic cell | 14 studies | 37% ± 19% | |
monocyte | 14 studies | 41% ± 23% | |
ciliated cell | 14 studies | 38% ± 14% | |
basal cell | 13 studies | 38% ± 16% | |
mast cell | 12 studies | 45% ± 14% | |
conventional dendritic cell | 10 studies | 26% ± 9% | |
myeloid cell | 10 studies | 50% ± 18% | |
adipocyte | 10 studies | 35% ± 13% | |
club cell | 9 studies | 44% ± 16% | |
pericyte | 9 studies | 27% ± 12% | |
alveolar macrophage | 8 studies | 44% ± 26% | |
type I pneumocyte | 8 studies | 33% ± 8% | |
regulatory T cell | 8 studies | 31% ± 20% | |
T cell | 8 studies | 39% ± 17% | |
type II pneumocyte | 7 studies | 31% ± 7% | |
epithelial cell | 7 studies | 36% ± 20% | |
plasmacytoid dendritic cell | 7 studies | 21% ± 6% | |
hematopoietic precursor cell | 6 studies | 41% ± 25% | |
respiratory goblet cell | 6 studies | 46% ± 26% | |
leukocyte | 6 studies | 50% ± 24% | |
CD4-positive, alpha-beta T cell | 6 studies | 37% ± 15% | |
CD8-positive, alpha-beta T cell | 6 studies | 33% ± 16% | |
natural killer cell | 6 studies | 37% ± 16% | |
non-classical monocyte | 5 studies | 24% ± 7% | |
hematopoietic stem cell | 5 studies | 34% ± 20% | |
lymphocyte | 5 studies | 47% ± 23% | |
brush cell | 5 studies | 44% ± 17% | |
B cell | 5 studies | 41% ± 9% | |
duct epithelial cell | 4 studies | 34% ± 14% | |
secretory cell | 4 studies | 26% ± 5% | |
GABAergic neuron | 4 studies | 38% ± 15% | |
endothelial cell | 4 studies | 25% ± 7% | |
glutamatergic neuron | 4 studies | 38% ± 15% | |
mucosal invariant T cell | 4 studies | 29% ± 16% | |
plasma cell | 4 studies | 29% ± 6% | |
mononuclear phagocyte | 4 studies | 40% ± 17% | |
luminal hormone-sensing cell of mammary gland | 4 studies | 60% ± 8% | |
smooth muscle cell | 4 studies | 28% ± 9% | |
myoepithelial cell | 4 studies | 34% ± 7% | |
cholangiocyte | 3 studies | 42% ± 9% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 36% ± 18% | |
common myeloid progenitor | 3 studies | 35% ± 11% | |
pro-B cell | 3 studies | 21% ± 0% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 33% ± 13% | |
tissue-resident macrophage | 3 studies | 38% ± 18% | |
adventitial cell | 3 studies | 28% ± 11% | |
myofibroblast cell | 3 studies | 36% ± 22% | |
goblet cell | 3 studies | 36% ± 25% | |
astrocyte | 3 studies | 40% ± 33% | |
neuron | 3 studies | 37% ± 23% | |
CD8-positive, alpha-beta memory T cell | 3 studies | 20% ± 6% | |
mucus secreting cell | 3 studies | 58% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 7488.53 | 458 / 459 | 100% | 49.25 | 1115 / 1118 |
lung | 100% | 6416.87 | 578 / 578 | 99% | 28.85 | 1149 / 1155 |
stomach | 90% | 2582.58 | 324 / 359 | 99% | 22.83 | 284 / 286 |
intestine | 83% | 1768.99 | 805 / 966 | 98% | 19.56 | 517 / 527 |
bladder | 76% | 3415.05 | 16 / 21 | 97% | 19.95 | 491 / 504 |
skin | 99% | 4600.72 | 1792 / 1809 | 73% | 11.75 | 346 / 472 |
prostate | 99% | 4161.34 | 242 / 245 | 68% | 7.18 | 339 / 502 |
thymus | 84% | 1533.40 | 547 / 653 | 80% | 15.19 | 486 / 605 |
ovary | 76% | 1829.38 | 137 / 180 | 81% | 13.92 | 349 / 430 |
esophagus | 58% | 1235.16 | 832 / 1445 | 98% | 29.88 | 179 / 183 |
pancreas | 41% | 588.07 | 133 / 328 | 96% | 30.26 | 170 / 178 |
uterus | 35% | 538.05 | 60 / 170 | 95% | 19.34 | 435 / 459 |
kidney | 51% | 933.03 | 45 / 89 | 68% | 10.60 | 611 / 901 |
spleen | 100% | 3098.74 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.36 | 1 / 1 |
adipose | 100% | 4278.18 | 1202 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 21.85 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 97% | 13.63 | 28 / 29 |
peripheral blood | 95% | 2459.35 | 885 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 93% | 2392.27 | 1242 / 1335 | 0% | 0 | 0 / 0 |
liver | 59% | 798.30 | 133 / 226 | 27% | 2.94 | 108 / 406 |
muscle | 83% | 3186.97 | 665 / 803 | 0% | 0 | 0 / 0 |
adrenal gland | 71% | 910.66 | 183 / 258 | 11% | 1.20 | 25 / 230 |
brain | 13% | 135.92 | 333 / 2642 | 33% | 4.43 | 236 / 705 |
heart | 45% | 913.89 | 389 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.07 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043371 | Biological process | negative regulation of CD4-positive, alpha-beta T cell differentiation |
GO_0030097 | Biological process | hemopoiesis |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0002062 | Biological process | chondrocyte differentiation |
GO_0030854 | Biological process | positive regulation of granulocyte differentiation |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0061026 | Biological process | cardiac muscle tissue regeneration |
GO_0071425 | Biological process | hematopoietic stem cell proliferation |
GO_0032743 | Biological process | positive regulation of interleukin-2 production |
GO_0060043 | Biological process | regulation of cardiac muscle cell proliferation |
GO_0030182 | Biological process | neuron differentiation |
GO_1903055 | Biological process | positive regulation of extracellular matrix organization |
GO_0032967 | Biological process | positive regulation of collagen biosynthetic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0043378 | Biological process | positive regulation of CD8-positive, alpha-beta T cell differentiation |
GO_0045595 | Biological process | regulation of cell differentiation |
GO_0048935 | Biological process | peripheral nervous system neuron development |
GO_1905203 | Biological process | regulation of connective tissue replacement |
GO_0002573 | Biological process | myeloid leukocyte differentiation |
GO_0010755 | Biological process | regulation of plasminogen activation |
GO_0001503 | Biological process | ossification |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016513 | Cellular component | core-binding factor complex |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | RUNX1 |
Protein name | RUNX1 mutant RUNX family transcription factor 1 Runt-related transcription factor 1/NDC1 transmembrane nucleoporin fusion protein Runt-related transcription factor RUNX1 protein Mutant RUNX1 RUNX1/RUNX1T1 fusion protein Runt-related transcription factor 1 (Acute myeloid leukemia 1 protein) (Core-binding factor subunit alpha-2) (CBF-alpha-2) (Oncogene AML-1) (Polyomavirus enhancer-binding protein 2 alpha B subunit) (PEA2-alpha B) (PEBP2-alpha B) (SL3-3 enhancer factor 1 alpha B subunit) (SL3/AKV core-binding factor alpha B subunit) |
Synonyms | CBFA2 TMEM48 AML1 fusion RUNX1T1 |
Description | FUNCTION: Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (Probable). Essential for the development of normal hematopoiesis . Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter . Inhibits KAT6B-dependent transcriptional activation (By similarity). Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity). Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells . Positively regulates the expression of RORC in T-helper 17 cells (By similarity). .; FUNCTION: Isoform AML-1G shows higher binding activities for target genes and binds TCR-beta-E2 and RAG-1 target site with threefold higher affinity than other isoforms. It is less effective in the context of neutrophil terminal differentiation. .; FUNCTION: Isoform AML-1L interferes with the transactivation activity of RUNX1. . FUNCTION: Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. . |
Accessions | X5CC30 Q2TAM6 ENST00000300305.7 [Q01196-8] ENST00000416754.1 C9JWM1 ENST00000344691.8 [Q01196-1] ENST00000482318.5 ENST00000475045.6 V9GYT3 ENST00000399237.6 ENST00000399240.5 ENST00000437180.5 [Q01196-8] X5C9T4 X5CR08 ENST00000675419.1 [Q01196-8] X5C9T0 Q01196 X5C3Z9 X5CT67 X5C404 U5P039 A0A0C4DG58 H9KVB1 X5CR12 A8MZI9 ENST00000358356.9 [Q01196-3] X5CT71 V9GYT5 X5CR15 A0A6M6RJQ2 A0A7D4XPZ8 ENST00000455571.5 X5CC24 A0A023PPR2 |